What is Lixte Biotechnology Holdings Interest Expense?
Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Lixte Biotechnology Holdings's interest expense for the
three
months ended in Mar. 2024 was $ -0.01 Mil.
Its interest expense for the trailing twelve months (TTM) ended in Mar. 2024 was $-0.02 Mil.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Lixte Biotechnology Holdings's Operating Income for the
three
months ended in Mar. 2024 was $ -0.97 Mil. Lixte Biotechnology Holdings's Interest Expense for the
three
months ended in Mar. 2024 was $ -0.01 Mil.
Lixte Biotechnology Holdings did not have earnings to cover the interest expense.
The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
Lixte Biotechnology Holdings Interest Expense Calculation
Interest Expense is the amount reported by a company or individual as an expense for borrowed money.
Interest Expense for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.02 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Lixte Biotechnology Holdings (NAS:LIXT) Interest Expense Explanation
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense. The higher, the better.
Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
Lixte Biotechnology Holdings's Interest Expense for the
three
months ended in Mar. 2024 was $-0.01 Mil. Its
Operating Income
for the
three
months ended in Mar. 2024 was $-0.97 Mil. And its Long-Term Debt & Capital Lease Obligation for the
three
months ended in Mar. 2024 was $0.00 Mil.
Lixte Biotechnology Holdings's Interest Coverage for the quarter that ended in Mar. 2024 is calculated as
| Lixte Biotechnology Holdings did not have earnings to cover the interest expense. |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
The higher the ratio, the stronger the company's financial strength is.
Lixte Biotechnology Holdings (Lixte Biotechnology Holdings) Business Description
Traded in Other Exchanges
N/A
Address
680 East Colorado Boulevard, Suite 180, Pasadena, CA, USA, 91101
Lixte Biotechnology Holdings Inc is a drug discovery company that has a developed unique, proprietary, first-in-class protein phosphatase inhibitor, LB-100, as its lead clinical compound. LB-100 has potential widespread use as an anti-cancer agent when used alone and in combination with standard anti-cancer therapies, including cytotoxic drugs, radiation, and immune checkpoint blockers. The Company's product pipeline is primarily focused on inhibitors of protein phosphatases, used alone and in combination with cytotoxic agents and x-ray and immune checkpoint blockers.
Executives
| Rene Bernards |
director |
KONINGSVAREN 37, ABCOUDE P7 1391AD |
| Van Der Baan Bastiaan Jeroen |
director |
HOGEWEG 4-H, AMSTERDAM P7 1098CB |
| Eric Forman |
10 percent owner |
117 E. 29TH ST., APT. 5A, NEW YORK NY 10016 |
| Regina Brown |
director |
248 ROUTE 25A, NO. 2, EAST SETAUKET NY 11733 |
| Glenn Krinsky |
10 percent owner |
C/O SRKP 1, INC., 1900 AVENUE OF THE STARS, SUITE 310, LOS ANGELES CA 90067 |
| Yun Yen |
director |
1301 OAKLAWN ROAD, ARCADIA CA 91006 |
| Robert Greenberg |
10 percent owner |
SKECHERS USA INC, 228 MANHATTAN BEACH BLVD, MANHATTAN BEACH CA 90266 |
| Gil Schwartzberg |
10 percent owner |
269 S. BEVERLY DR., #1315, BEVERLY HILLS CA 90212 |
| Philip F Palmedo |
director |
1801 CENTURY PARK EAST #1600, LOS ANGELES CA 90067 |
| John S Kovach |
director, 10 percent owner, officer: Pres., CFO & Secty |
1801 CENTURY PARK EAST #1600, LOS ANGELES CA 90067 |
| Stephen J. Forman |
director |
248 ROUTE 25A, NO. 2, EAST SETAUKET NY 11733 |
| Hung Tak Ho |
10 percent owner |
MAYFAIR BY THE SEA II, TOWER T8, 1/F, UNIT A, 21 FO CHUN ROAD, PAK SHEK KOK, TAIPO K3 00000 |
| Robert N Weingarten |
officer: Vice President and CFO |
5439 LOCKHURST DRIVE, WOODLAND HILLS CA 91367 |
| James Miser |
officer: Chief Medical Officer |
680 E COLORADO BLVD., SUITE 180, PASADENA CA 91101 |
| Jane Merrill Riggs |
10 percent owner |
4852 SAINT ANDRES AVENUE, LA VERNE CA 91750 |
Lixte Biotechnology Holdings (Lixte Biotechnology Holdings) Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
LIXT has been successfully added to your 